In Safe Hands Protein and peptide biomarker solutions for pharmaceutical and diagnostics applications
Ahead of the Pack Protein and peptide biomarker solutions for pharmaceutical and diagnostics applications
Reaching new heights in biomarker solutions Protein and peptide biomarker solutions for pharmaceutical and diagnostics applications
Setting New Standards Protein and peptide biomarker solutions for pharmaceutical and diagnostics applications
Leading from the Front Protein and peptide biomarker solutions for pharmaceutical and diagnostics applications

Biomarker Assays

Biomarker Assays
Rapid development of TMT-SRM mass spectrometry assays for biomarker validation and routine measurement Learn More

Biomarker Services

Biomarker Services
Unique peptidomic and proteomic workflows using TMT with LTQ Orbitrap for maximum coverage in discovery and validation Learn More

Proprietary Biomarkers

Proprietary Biomarkers
Biomarkers for Alzheimer's disease, stroke, cancer and other indications Learn More

What's new

In a Post-Conference Press Release from the Kuopio Alzheimer's Symposium- Dr. Ian Pike discusses a new testing method that can identify memory patients who are likely to develop Alzheimer's disease within one year. "The test is taken from a blood sample and it is 87% accurate."

Learn More

News

23 Jun, 2015 / Mapping the future for personalised medicine- Annual Report & Accounts 2014 Our breakthrough science and trusted proprietary technologies for protein biomarker discovery, validation and assay development puts us in a position of great privilege, leading the way in one of the most exciting areas of personalised medicine.
Read More
23 Jun, 2015 / Publication of Annual Report 2014 The Company announces that its Annual Report and Accounts for the year ended 31 December 2014, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company’s website at www.proteomics.com, and will be posted to shareholders…
Read More
23 Jun, 2015 / Placing to raise £2.5 million Proteome Sciences plc (AIM:PRM) is pleased to announce it has conditionally raised approximately £2.5 million, before expenses, through the placing of 13,861,112 new ordinary shares of 1 penny each in the capital of the Company
Read More

Events

18-23 Jul, 2015 /AAIC International Conference

AAIC Image  PS Poster/Oral Presentations:

  • Comprehensive profile of CSF Tau phosphorylation–Combination of TMTcalibratorTM SysQuant®
  • Early microglia markers of neuroinflamation- TMTcalibratorTM
  • Analysis of common datasets reveals pharmacodynamic biomarkers–Cross validation using TMTcalibratorTM SysQuant® 
  • Identifying Tau related pathways in AD– SysQuant®
  • Disease specific forms of Clusterin for AD prognosis– TMT®-SRM

Meet the team at AAIC-Read More


31 Aug-2 Sept, 2015 
/Biomarkers & Clinical Research

  International Conf. on Biomarkers & Clinical Research  Plenary Presentation by Dr. CheeGee See

  • Proteomic strategies to overcome tumor resistance to oncology targeted medicines.

Meet the team at BCRC- Read More

All 2015 Events